Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum Resistant Epithelial Ovarian Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05422183
What this trial is testing

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer, Epithelial
Zhongda Hospital 20
Testing effectiveness (Phase 2)Study completedNCT03268382
What this trial is testing

P53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Who this might be right for
High-grade Serous Ovarian Cancer
Aprea Therapeutics 36
Large-scale testing (Phase 3)Study completedNCT01684878
What this trial is testing

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Who this might be right for
Ovarian Cancer
Hoffmann-La Roche 208
Testing effectiveness (Phase 2)Study completedNCT01283035
What this trial is testing

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Who this might be right for
Ovarian SarcomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)WithdrawnNCT04561817
What this trial is testing

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Icahn School of Medicine at Mount Sinai
Testing effectiveness (Phase 2)Study completedNCT01652079
What this trial is testing

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Massachusetts General Hospital 63
Testing effectiveness (Phase 2)Study completedNCT00466960
What this trial is testing

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Who this might be right for
Brenner TumorFallopian Tube CancerOvarian Clear Cell Cystadenocarcinoma+9 more
University of Washington 21
Early research (Phase 1)Looking for participantsNCT04633239
What this trial is testing

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
National Cancer Institute (NCI) 42
Early research (Phase 1)WithdrawnNCT02083536
What this trial is testing

LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Who this might be right for
Ovarian CancerOvarian CarcinomaRecurrent Ovarian Cancer+1 more
University of Miami
Large-scale testing (Phase 3)Not Yet RecruitingNCT07545460
What this trial is testing

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 404
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07591831
What this trial is testing

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian CancerFallopian Tube CancersEpithelial Ovarian Cancer+1 more
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00091377
What this trial is testing

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
MEI Pharma, Inc. 65
Testing effectiveness (Phase 2)Looking for participantsNCT06799065
What this trial is testing

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Who this might be right for
Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+4 more
Accent Therapeutics 218
Early research (Phase 1)Study completedNCT03213964
What this trial is testing

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota 10
Large-scale testing (Phase 3)Study completedNCT00382811
What this trial is testing

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Who this might be right for
Fallopian Tube CancerPeritoneal NeoplasmsOvarian Cancer
MEI Pharma, Inc. 142